13F Holdings
中文EN

IMDX Insight Molecular Diagnostics Inc.

In Vitro & In Vivo Diagnostic Substances · Nasdaq · SEC CIK 1642380 · Fiscal year ends 12/31

Financial factors as of 2025-09-30 (2025Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY520.9%
TTM net income YoY-40.9%
TTM EPS YoY27.5%
Revenue 3-yr CAGR1.0%
Net income 3-yr CAGR—

Margins

Gross margin54.5%
Operating margin-1,392.9%
Net margin-1,380.7%
FCF margin-540.3%
EBITDA margin-1,343.0%

Returns

ROE-23,603.1%
ROA-106.5%
ROIC (approx.)—
Asset turnover0.08x

Leverage & solvency

Liabilities / assets120.9%
Debt / equity—
Current ratio2.79x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.36x
Accruals ratio-68.2%
Payout ratio—
Capex / revenue43.6%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$4.05M$1.88M$1.50M$958,000$2.20M
Cost of revenue$1.75M$1.05M$1.00M$880,000$697,000
Gross profit$2.30M$740,000$413,000-$18,000$1.42M
R&D expense$15.90M$9.84M$9.29M$7.30M$5.04M
SG&A expense$10.63M$10.20M$11.18M$21.88M$22.29M
Operating income-$51.12M-$61.04M-$25.14M-$18.00M-$53.73M
Pretax income—-$60.66M-$24.86M-$18.61M-$52.87M
Income tax$0$0$0—-$9.26M
Net income-$50.22M-$60.66M-$27.78M-$72.90M-$64.10M
EBITDA-$48.93M-$59.48M-$23.46M-$16.47M-$52.92M
EPS (basic)-1.65-4.66-3.75-13.25-0.72
EPS (diluted)-1.65-4.66-3.75-13.25-0.72
Weighted avg. shares (diluted)30.48M13.07M7.65M5.54M88,920
Banking
Net interest income-$109,000-$84,000-$52,000-$83,000-$209,000
Balance sheet
Cash & equivalents$11.58M$8.64M$9.43M$19.99M$32.95M
Receivables$1.13M$1.61M$484,000$2.01M$1.44M
Inventory$446,000$410,000———
Current assets$15.31M$11.76M$10.70M$25.54M$39.14M
PP&E, net$6.43M$6.32M$4.71M$8.71M$7.13M
Goodwill————$18.68M
Intangibles$0$14.61M$56.59M$61.63M$61.72M
Total assets$25.76M$35.08M$74.89M$100.09M$159.56M
Current liabilities$12.07M$7.28M$7.19M$12.11M$14.12M
Total liabilities$57.22M$47.35M$49.30M$60.50M$94.35M
Shareholders' equity-$31.46M-$12.27M$20.47M$34.29M$65.22M
Shares outstanding28.68M17.45M8.26M5.93M92.23M
Cash flow statement
Operating cash flow-$22.18M-$20.69M-$23.32M-$45.57M-$35.94M
Capital expenditure$3.19M$516,000$281,000$4.34M$2.25M
Free cash flow-$25.37M-$21.20M-$23.61M-$49.91M-$38.19M
Investing cash flow-$3.19M-$512,000-$932,000-$4.34M-$13.96M
Financing cash flow$28.07M$20.43M$12.19M$35.81M$78.36M
Depreciation & amortization$2.20M$1.56M$1.68M$1.53M$800,000
Stock-based compensation$2.22M$1.75M$2.76M$10.04M$6.84M

Free plan shows the latest 5 periods; Pro shows all 12 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.